Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.
Inclusion Criteria:
Exclusion Criteria:
Atlanta, Georgia 30322, United States
Baltimore, Maryland 21201-1544, United States
Boston, Massachusetts 02111-1552, United States
New Brunswick, New Jersey 08903-0010, United States
Norfolk, Virginia 23507-1904, United States
Vienna, 1090, Austria
Beijing, 100029, China
Essen, 45122, Germany
Giessen, 35392, Germany
Hamburg, 20246, Germany
Homburg/Saar, 66421, Germany
Munich, 81377, Germany
Hong Kong, Hong Kong
Budapest, 1096, Hungary
Pécs, 7624, Hungary
Mumbai, 400012, India
Haifa, 34362, Israel
Petach - Tikvah, 49100, Israel
Bucharest, 050159, Romania
Moscow, 101990, Russia
Moscow, 105077, Russia
Moscow, 117049, Russia
Moscow, 121552, Russia
Saint Petersburg, 193015, Russia
Saint Petersburg, 197 022, Russia
Saint Petersburg, 197341, Russia
Tomsk, 634012, Russia
Yaroslavl, 150 003, Russia
Yekaterinburg, 620102, Russia
Belgrade, 11000, Serbia
Belgrade, 11080, Serbia
Bratislava, 833 48, Slovakia
Bratislava, 833 48, Slovakia
Taipei, 100, Taiwan
Bangkok, 10400, Thailand
Khon Kaen, 40002, Thailand
Dnipro, 49060, Ukraine
Odesa, 65044, Ukraine